BBOT (BridgeBio Oncology Therapeutics) PB Ratio: 1.81 (As of Jul. 07, 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics PB Ratio?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 PB Ratio is 1.81 as of Jul. 07, 2026. GuruFocus rates BBOT with a GF Score™ of 12/100. Among 1,230 Biotechnology companies, BridgeBio Oncology Therapeutics ranks better than 68.37% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), BridgeBio Oncology Therapeutics's share price is $8.40. BridgeBio Oncology Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $4.65. Hence, BridgeBio Oncology Therapeutics's PB Ratio of today is 1.81.

The historical rank and industry rank for BridgeBio Oncology Therapeutics's PB Ratio or its related term are showing as below:

BBOT' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.85
Current: 1.81

During the past 3 years, BridgeBio Oncology Therapeutics's highest PB Ratio was 1.85. The lowest was 0.00. And the median was 0.00.

BBOT's PB Ratio is ranked better than
68.37% of 1230 companies
in the Biotechnology industry
Industry Median: 2.99 vs BBOT: 1.81

Back to Basics: PB Ratio


BridgeBio Oncology Therapeutics  (NAS:BBOT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


BridgeBio Oncology Therapeutics PB Ratio Related Terms


BridgeBio Oncology Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics PB Ratio Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
PB Ratio
0.00 0.00 2.44

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 2.05 2.44 1.93

BBOT vs FTH, MNPR, MDXG: PB Ratio Comparison

For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Oncology Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where BridgeBio Oncology Therapeutics's PB Ratio falls into.


BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

BridgeBio Oncology Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=8.40/4.648
=1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 1.81 mean?
BridgeBio Oncology Therapeutics (BBOT) has a PB Ratio of 1.81 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #389 out of 1230 companies in the Biotechnology industry, placing it in the top 31.6%.
Is BridgeBio Oncology Therapeutics' PB Ratio too high?
BridgeBio Oncology Therapeutics' current PB Ratio is 1.81. The Biotechnology industry median PB Ratio is 2.99. BridgeBio Oncology Therapeutics' value of 1.81 is 39.5% below this industry median. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #389 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' PB Ratio compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #389 out of 1230 companies for PB Ratio. This puts BridgeBio Oncology Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.99. BridgeBio Oncology Therapeutics' value of 1.81 is 39.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Oncology Therapeutics's current PB Ratio of 1.81 is 39.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BridgeBio Oncology Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Oncology Therapeutics's current PB Ratio is 1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current PB Ratio of 1.81. The current PB Ratio is 1.81 and 39.5% below the Biotechnology industry median of 2.99. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current PB Ratio is 1.81 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price